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Inflammatory bowel disease affects more than 2 million people in Europe, with almost 20% of patients being
diagnosed in pediatric age. Patients with inflammatory bowel disease are at increased risk of thromboembolic
complications which may affect patients’ morbidity and mortality. The risk of the most common thromboembolic
events, such as deep venous thrombosis and pulmonary embolism, are estimated to be three-fold increased
compared to controls, but many other districts can be affected. Moreover, patients with ulcerative colitis and
Crohn’s disease experience thromboembolic events at a younger age compared to general population. Many
factors have been investigated as determinants of the pro-thrombotic tendency such as acquired risk factors or genetic
and immune abnormalities, but a unique cause has not been found. Many efforts have been focused on the study
of abnormalities in the coagulation cascade, its natural inhibitors and the fibrinolytic system components and both
quantitative and qualitative alterations have been demonstrated. Recently the role of platelets and microvascular
endothelium has been reviewed, as the possible link between the inflammatory and hemostatic process.
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Inflammatory bowel disease (IBD), whose major forms
are ulcerative colitis (UC) and Crohn’s disease (CD), is a
chronic inflammatory condition characterized by local
and systemic inflammation predominantly affecting the
gastrointestinal tract but that may be associated to
numerous extra-intestinal manifestations including
thrombosis. IBD affects more than 2 million people in
Europe, with almost 20% of patients being diagnosed in
pediatric age; in Italy over 200 thousands patients are
estimated to suffer from such diseases.
The association between IBD and venous thromboembol-
ism (VTE) was first described in 1936 by Bargen et al., who
observed 18 patients with VTE among over 1000 IBD
patients followed at the Mayo Clinic [1]. Since then, several
publications reported an increased risk of thromboembolic
events (TE) affecting both the venous and arterial district
in UC and CD patients. This condition seems to be a
characteristic of IBD, not simply of inflammatory or
intestinal chronic disease, because it has not been* Correspondence: martina.giannotta@gmail.com
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unless otherwise stated.demonstrated in other conditions such as rheumatoid
arthritis or coeliac disease [2,3]. The overall incidence
of VTE in IBD patients is estimated to be 1%-8%
[2-4] although necroscopy studies report higher rates,
approximately 40% [5-8]. No significant difference
was found in the risk of VTE between UC and CD
patients. The risk of VTE in lower extremities and
pulmonary embolism in IBD patients is reported to
be 3-fold increased compared to the general population
[3,9,10] even after correction for known pro-thrombotic
factors [6,7]. Other venous districts may occasionally be
involved as the cerebral [11], hepatic and portal [12],
retinal [13] and mesenteric veins [14]. Arterial thrombosis
occur less frequently but has been described especially in
cerebral, retinal and limbs arteries [15-17]. Some authors
also reported an increased incidence of coronary [18] and
aortic [19] thrombotic involvement in young IBD patients.
IBD patients experiencing a VTE episode were generally
younger compared to the general population [20], with
the young age of first VTE being associated with a higher
risk of recurrence [21]. The overall mortality rate per
episode is estimated to be as high as 25% [9]. The risk of
TE is estimated to be almost three times higher in males
than in females [21]. Some authors reported an increasedral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Table 1 Acquired risks factors for thrombosis in IBD
1 Fluid depletion
2 Surgery
3 Central venous catheters
4 Immobilization
5 Steriod therapy
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the non-IBD obstetric population [22,23], but others did
not [24]. Generally most of TE occur during active disease,
even if a high rate of thrombosis (almost one third) is
reported during remission and well controlled disease,
supporting the hypothesis of a greater pro-thrombotic ten-
dency in IBD independent of disease activity [25,26]. The
incidence of TE also correlates with the extent of the
disease, i.e. especially pancolonic involvement in UC or
colonic involvement in CD [27,28], and with the presence of
complications such as fistulas, abscesses or strictures [28].
The pathogenesis of thrombosis in IBD is complex
and not fully explained. It is thought to be multifactorial
as no consistent unifying etiology has been found yet.
Numerous investigations have been conducted on major
pro-thrombotic genetic predispositions and IBD, but no
significant association has been found to explain the
increased VTE risk both in UC and CD patients [29-31].
Many reports tried to explain the increased risk of
TE in IBD focusing on the different components of
the coagulation cascade demonstrating both qualitative and
quantitative abnormalities in procoagulant, anticoagulant
and fibrinolytic factors, although others could not find any
identifiable reason in approximately half IBD patients
which developed TE [32]. Finally, interesting results have
been found observing that in patients with inherited
bleeding disorders (hemophilia A and B, von Willebrand
disease) UC and CD occurred less frequently than in
general population, giving indirect evidence that vascular
thrombosis may be involved in IBD pathogenesis and in
the inflammatory process [33].
Acquired risks factors for thrombosis in IBD
Many acquired factors may affect hemostatic system and
contribute to the pathophysiology of VTE in IBD patients.
They include fluid depletion, prolonged immobilization,
surgery, the use of central venous catheters, steroid ther-
apy, oral contraceptives or hormone replacement therapy,
cigarette smoking and vitamin deficiency leading to
hyperhomocysteinemia [34,35]. In particular, hyperho-
mocysteinemia is known to be and independent risk
factor for both atherosclerotic vascular disease and
VTE [36], even if recently it has been considered more as
a risk “marker” than as a true risk factor for thrombosis. A
recent study reported significantly higher homocysteine
plasma levels in UC and CD patients compared to
controls, but the prevalence of hyperhomocysteinemia
was not different within IBD patients which did or did not
experience TE [37]. It is thought that folate deficiency
related to the use of some medications (i.e. methotrexate
or sulfasalzine) may lead to hyperhomocysteinemia in
these patients although B6 and B12 vitamin or genetic
mutations may also contribute to TE [36]. Acquired risk
factors for thrombosis in IBD are summarized in Table 1.Genetic risks factors for thrombosis in IBD
The most frequent causes of inherited thrombophilia in
the general population are the prothrombin G20210A
polymorphismfactor and V Leiden, a genetic polymorph-
ism that makes activated factor V relatively resistant to
degradation by activated protein C. Less relevant is the
C677T polymorphism of methylenetetrahydrofolate reduc-
tase (MTHFR) gene that favors hyperhomocysteinemia.
These genetic mutations have been studied in IBD popula-
tion but no significant difference has been found in their
incidence in IBD patients when compared to health
controls, nor in IBD patients that experienced or not TE
[38,39]. An inherited polymorphism (Val34Leu) of factor
XIII which protects against thrombosis has been evaluated
in IBD patients and no difference has been found versus
the general population [40,41]. Finally protein C, protein S
and antithrombin deficiencies have also been investigated
and they seem to have no increased prevalence among IBD
patients independently of previous history of TE [36].
In conclusion, in spite of the big effort in terms of
numerous genetic studies performed, no significant
association has been demonstrated to date between
genetic factors cause of hyper-coagulability and IBD.
Thus, genetics of thrombophilia does not explain the
increased TE risk in CD and UC patients, suggesting
a most relevant role of acquired factors.
Abnormalities of the coagulation cascade in IBD
The coagulation cascade is a series of enzymatic conver-
sions ending in the formation of thrombin which converts
fibrinogen (plasma soluble precursor) in fibrin (insoluble
fibrous protein). The cascade has classically been divided
into two branches: the extrinsic pathway initiated by tissue
damage with exposition of tissue factor (TF) to blood,
relevant for most conditions of clotting activation, and the
intrinsic pathway which plays a role mainly in the mecha-
nisms of amplification. The two ways converge at the
point where factor X is activated, eventually leading to
prothrombin cleavage and thrombin formation. A sche-
matic representation of coagulation cascade and natural
anticoagulant system is provided in Figure 1.
Figure 1 Schematic representation of coagulative cascade and of natural anticoagulant system.
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quantitative and qualitative alterations of many coagulation
enzymes, some of which are also considered acute-phase
reactants. This includes elevation of circulating fibrinogen,
prothrombin, and factors V (FV), VII (FVII), VIII (FVIII),
X (FX), XI (FXI) and XII (FXII) [3,42-47]. Moreover, many
other alterations reflecting a state of hyper-coagulability
have been reported in IBD patients, such as elevation of
prothrombin factor 1 + 2 (side-products of prothrombin
cleavage), thrombin-antithrombin complex (TAT), fibrino-
peptide A (FPA) and B (FPB) and decreased factor
XIII (FXIII) levels [4,42,43,45,47,48]. These findings are
consistent with an activation, which may sometimes be
subclinical, of coagulation system in IBD. It is still debated
if this condition is just a consequence of the inflammatory
state or a feature of the intestinal disease per se regardless
of disease activity [43,49]. In particular, decreased levels of
FXIII, which is involved in the cross-linking of fibrin, have
been reported mostly during active disease but FXIII
mucosal deposits have been found both in affected and
macroscopically normal bowel samples [43,49]. This is
thought to reflect FXIII chronic consumption because of
the increased formation of microthrombi in the vessels ofinflamed enteric mucosa, or the repair of injured tissue
[50,51]. Another mechanism that may be implicated in
generating the pro-thrombotic state in IBD patients is
thought to involve the cell components known as
“microparticles” which are vesicles of cell membrane -
mainly derived from platelets - released by cells, when
activated, or during apoptosis. Microparticles have
procoagulant properties because of the expression of TF
on their surface and are implicated in modulation of
endothelial activity and in inflammatory processes [52].
The circulating concentration of microparticles has been
found to be elevated in IBD patients during active phases
of the disease, suggesting a potential role in the procoagu-
lant tendency [53]. Abnormalities of coagulation cascade
in IBD are summarized in Table 2.
Abnormalities of the natural coagulation inhibitors in IBD
A pro-thrombotic condition may result from a decrease
in natural anticoagulant factors. The system of natural
coagulation inhibitors is composed by antithrombin
(AT), protein C (PC) pathway and TF pathway inhibitor
(TFPI). AT is a physiological inhibitor of thrombin and
FIXa, FXa, FXIa and FXIIa and its activation is triggered
Table 2 Abnormalities in coagulation, anticoagulation





↑ Fibrinogen ↓ tPA ↓ AT III
↑ Prothrombin ↑ PAI-1 ↓ TFPI
↑ Factors: Va, VIIa, VIIIa, Xa,XIa, XIIa ↑ TAFI Conflicting data
about PS and PC
↑ Prothrombin factors 1+2
↑ Thrombin-antithrombin III
complex (TAT)
↑ Fibrinopeptide A and B
↑ Microparticles
↓ Factor XIII
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tered. TFPI is a protein produced by the vascular endothe-
lium and by megakaryocytes, and is an inhibitor of the
TF-depending coagulation cascade and a raker of endo-
thelial damage [54,55]. The PC pathway is a complex
system which also involves protein S (PS) and several
membrane receptors such as TM and endothelial protein
C receptor (EPCR). PC is activated, especially if bounded
to the EPRC, by the complex thrombin-TM. Once
activated, in the presence of the cofactor PS, PC is able to
inactivate FVIIIa and FVa and also has pro-fibrinolytic
properties by binding PAI-1 [54,56]. See Figure 1 for
schematic representation of coagulation cascade and
natural anticoagulant system.
Data about the plasma concentration of natural coagula-
tion inhibitors in IBD patients are conflicting: some authors
reported no differences in PS [3,57,58] and AT [49,59]
levels between IBD patients and controls, whereas others
described a decrease in AT, TFPI, PC and PS in active vs
inactive disease or vs controls [43,56,57,60]; finally some
others found higher levels of PC and PS in IBD patients vs
controls [43]. Some studies reported higher concentrations
of TM in active CD and UC [61]. It is possible that changes
in systemic levels of these factors do not necessarily reflect
the local loss of inhibition of coagulation occurring within
the enteric mucosa, where a loss of function of natural
anticoagulants may occur [56].
Which seems important to remark is that there is a
growing body of evidence that AT and TM are implicated
in the inflammatory process. AT, when present at high
concentrations [33], has been demonstrated to reduce the
inflammatory response by decreasing leukocyte adhesion
(by reducing expression of CD11b/CD18 cell surface
receptors), TF and IL6 expression in monocytes and
endothelium [55]. Furthermore AT seems to increase
endothelial prostacyclin formation and inhibits endothelial
pro-inflammatory mediators production by decreasing
nuclear factor (NFkB) activation [54,62-64]. TM also seemsto affect the course of inflammatory process, apoptosis and
endothelial barrier integrity [54,55] and it has been
suggested that increased TM levels may be associated
with anti-inflammatory properties [61]. Abnormalities of
coagulation inhibitors in IBD are summarized in Table 2.
Abnormalities of the fibrinolytic system in IBD
Normally the fibrinolytic system allows fibrin clot
removal by plasmin activity which also inhibits several
coagulation factors. Disturbances in the fibrinolysis
may be associated with hyper or hypo-coagulability.
The two major activators of plasminogen to plasmin
are urokinase plasminogen activator (uPA) and tissue
plasminogen activator (tPA). The latter, which is released
in plasma by endothelial cells, is the most potent activator
of plasminogen and consequently the main regulator of
fibrinolysis. Its affinity to plasminogen is enhanced when
bound to a fibrin surface thus restricting fibrinolysis to the
site of clot [65,66]. The fibrinolytic system has potent
inhibitors such as plasminogen activator inhibitor 1
(PAI-1) that inhibits tPA activity in plasma [67],
alpha2-antiplasmin which inhibits plasmin activity in
plasma [68] and thrombin-activatable fibrinolysis inhibitor
(TAFI) which is responsible for the removal of carboxyl-
terminal lysine residues from partially degraded fibrin, so
decreasing the binding of tPA and plasminogen to the clot
and consequently decreasing fibrinolysis, and is also a
potent plasmin generation inhibitor. TAFI is activated by
thrombin, thrombin-TM complex and plasmin thus being
the direct link between coagulation and fibrinolytic
systems [69]. See Figure 2 for schematic representation of
the fibrinolytic system.
The circulating concentration of the fibrinolytic system’s
factors is impaired in UC and CD patients and favors the
pro-thrombotic mechanisms. In IBD patients a reduction
in fibrinolysis activators (such as tPA) and an increase in
inhibitors (such as PAI-1 and TAFI) has been described,
inducing a reduced activity of the system [49,70,71].
Recently the activated form of TAFI (TAFIa) has been
investigated because of its potential anti-inflammatory
properties with recognition of its ability to inactivate
anaphylotoxines, C3a, C5a and other pro-inflammatory
mediators [72,73]. Moreover a significant correlation has
been found in IBD patients between TAFIa, disease activity
and inflammatory markers such as CRP, fibrinogen and
platelets [73]. Abnormalities of the fibrinolytic system in
IBD are summarized in Table 2.
Abnormalities of the endothelium in IBD
Endothelium plays a central role in contributing to the
inflammatory process by regulating leukocytes adhesion
and transmigration and by the production of cytokines
and chemokines. Furthermore it is responsible for the
regulation of platelet adhesion and activation, and for
Figure 2 Schematic representation of the fibrinolytic system.
Giannotta et al. Thrombosis Journal  (2015) 13:14 Page 5 of 9the regulation of blood coagulation [56]. Endothelial
disfunction has been demonstrated in IBD and mar-
kers of its damage such as von Willebrand factor
(vWF), EPCR and TM are increased in IBD patients
serum and seem to correlate with disease activity
[74-77]. The knot seems to be an imbalance between
nitric oxide (NO), a vasodilator and anti-aggregant
agent, and reactive oxygen species (ROS) formation in
the inflamed endothelium [36]. In fact NO production
seems to be impaired in chronic inflamed IBD endo-
thelium both from NO synthase 2 (NOS2) deficient
transcription [78] and from induction of NOS competitor
arginase by inflammatory citokynes such as IL2 and
TNF-alpha [79]. On the other hand, an increased pro-
duction of ROS has been demonstrated within the
inflamed endothelium and it contributes to oxidative
stress in vWF molecules leading to the accumulation
of ultra-large vWF multimers - because of a reduced
sensitivity to ADAMTS-13 proteolytic activity - which are
most hemostatically active and favor platelet adhesion and
aggregation [36,80].
Endothelium plays a key role in inflammation due to
its ability to control the amount and type of leukocytes
that transmigrate to the interstitial space and to regulate
vascular tone and platelet adhesion and aggregation,
thus it directly affects the hemostatic system potentially
favoring thrombosis [56]. Which still remains unclear is
if the vascular involvement in IBD is a pathogenetic factor
or a consequence, inducing amplification of local and
systemic inflammation [81,82].Abnormalities of platelets in IBD
In IBD patients there are quantitative, morphological
and qualitative alterations in platelet characteristic.
Thrombocytosis and IBD have been first correlated in 1968
[83] and it is now well established that trombocytosis is
related to disease activity and severity [84]. Thrombocytosis
is considered a non specific response to inflammation
which may occur in chronic inflammatory conditions
other than IBD [25], but it has also been proposed that
thrombocytosis in UC and CD may reflect an aberration in
thrombopoiesis induced by greater plasma levels of throm-
bopoietin and IL6, which are involved in megakaryocytes
maturation process [85]. On the other hand, platelets in
IBD patients have smaller mean corpuscular volume
(MCV) than in controls [86], and platelet MCV seems to
be smaller during active phases of the disease as compared
to remission [56]. MCV has also been demonstrated to be
inversely proportional to some inflammation markers
levels such as C-reactive protein (CRP) and erythrocyte
sedimentation rate (ESR) so that this has been proposed as
a marker of disease activity [87]. It has been hypothesized
that during active disease platelet agglomerates (platelet-
platelet, platelet-leukocyte, platelet-endothelium) - that are
found to be elevated in IBD patients [88] - mainly involve
younger platelets with a higher MCV and consequently that
would relatively increase the circulating amount of older
and smaller platelets [89]. Moreover, platelets in IBD seem
to circulate in a chronic activated status and to be more
reactive and more sensitive to activation induced by
pro-aggregating agents. First of all, platelets have been
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patients, independently of disease severity, compared to
none of the healthy controls [90]. This was thought to be
a consequence of the inflammatory condition but it has
subsequently been demonstrated that platelet aggregates
are found in IBD patients but not in other inflammatory
diseases, thus being a specific characteristic of IBD [91].
The same author found an increase in surface and serum
platelet activation markers such as P-selectin, GP53 and
beta-thromboglobulin (beta-TG), whose increase was
independent from disease activity so suggesting that once
stimulated, platelets may remain chronically activated
even during remission phases of the disease [25,91]. In the
recent years another piece has come to partially complete
the picture. In fact, in CD and UC patients high values -
up to 4 times greater than healthy controls - of the surface
CD40 ligand (CD40L), an activation markers that allows
platelets to interact with a broad of immune and non
immune cells with pro inflammatory consequences
[25,92], and that acts as an inducer of the TF mediated
coagulation cascade [36] have been detected. Together
with its increase on the platelet surface, even the soluble
form of CD40L (sCD40L) in IBD patients serum is
increased - almost 15 fold compared to controls - as
released by such platelets [93]. High levels of sCD40L
have been associated with an increased risk of TE
[55]. Others reported that in vitro activated platelets
may directly increase CD40L expression in intestinal
endothelial cells favoring their interaction with numerous
immune cells and sustaining chronic inflammation [94].
Recent data reported an increased expression of CD40/
CD40L in the intestinal epithelial cells, in particular in
samples from inflamed ileal and colonic mucosa from CD
and UC patients, whereas that increase was not found in
uninvolved intestinal segments [95]. This finding provide,
for the first time, a piece of evidence of the interaction
between activated platelets and IBD affected intestinal
mucosa via the CD40/CD40L pathway [56]. That leads to
a key point: platelets could themselves act as inflammatory
cells and enhance the inflammatory process in IBD
mucosa. One of the first suggestion of the platelet role in
intestinal inflammation came from the finding of capillary
microthrombi in the mucosa of IBD patients, independ-
ently of the severity of inflammation. Those findings were
consistently absent in healthy subjects [96]. It has
then been suggested that platelet activation occurs in
the intestinal mucosa because of the finding of greater
platelet aggregates in the mesenteric blood of CD patients
[97]. This process has recently been reproduced in vitro
using human intestinal microvascular endothelial cells
(HIMEC) exposed to IL-1beta to mimic IBD endothelial
changes [25,93]. Activated CD40L positive platelets are
then thought to enhance themselves intestinal inflamma-
tion by the interaction with CD40 positive microvascularendothelium in the intestinal mucosa. That is thought
to be the trigger to up-regulation of endothelial IL8 pro-
duction and adhesion molecule expression (as ICAM-1
and VCAM-1) on the endothelium surface, leading to
inflammatory cell, specifically T-cell, recruitment and
inflammatory response amplification [25].
The role of inflammation
Inflammation and coagulation are two crucial systems
that are in balance and constantly influence each other
[25]. The impact of inflammation on coagulation has
been confirmed by several experimental studies showing
that inflammatory mechanism shift the hemostatic
balance to favor the activation of coagulation [36,54]
which, in turn, can also sustain inflammation promoting
a vicious circle between chronic inflammation and
thrombosis [25]. We have seen above how platelets,
endothelium and many components of the coagulation
cascade, fibrinolytic system and natural anticoagulant
inhibitors are directly involved in the inflammatory
process but other considerations need to be done.
Many studies reported that tumor necrosis factor
alpha (TNF-alpha), CD40L and CRP are able to induce
the expression of TF on the leucocytes cell surface, so
promoting activation of the intrinsic coagulation pathway
[98-100]. On the other hand, natural anticoagulant
pathways as the PC pathway and the heparin-AT pathway
have been demonstrated to be down-regulated by inflam-
matory citokynes as TNF-alpha and IL1beta [101,102].
Furthermore, CRP has been shown to inhibit TFPI [103]
and tPA [104] and to increase the expression of PAI-1
[105] leading to a more procoagulant tendency. Another
inflammatory citokyne, IL6, has been shown to have a
pro-thrombotic activity by increasing platelet production
and enhancing thrombin formation in concert with
TNF-alpha [106,107]. Another trigger to the procoagulant
profile by TNF-alpha is the down regulation of the
expression of anticoagulant TM and EPCR [108].
Recently, homocysteine has been shown to participate
to microvascular inflammation by triggering, together
with TNF-alpha, the expression of VCAM-1 and MCP-1
on endothelial surface thus leading to an enhanced
capacity to recruit T cells and monocytes [109].
Abnormalities of the immune system in IBD
Anti-phospholipid antibodies (APLA) are a group of
pro-thrombotic antibodies including lupus anticoagulant
(LAC), anti-cardiolipin antibodies (aCL) and anti-beta-2-
glicoprotein-I (anti-beta-2-GPI). APLA may be associated
with both venous and arterial thrombosis. IBD patients
seem to have higher rates of aCL and anti-beta-2-GPI
positivity - with an incidence of 20%-30% for the first and
9% for the latter - compared to general population, but
the real association with thrombosis in IBD is still unclear
Giannotta et al. Thrombosis Journal  (2015) 13:14 Page 7 of 9[110,111]. In fact, LAC, aCL and anti-beta-2-GPI levels
were similar in IBD patients with or without history of
VTE [36,110].
In IBD patients anti-PS antibodies have also been
detected, which may cause a reduction in the natural
anticoagulant potential but there is still not enough
evidence that they play any role in thrombotic risk [112].
Conclusions
Thrombotic mechanism in IBD patients is complex,
multifactorial and not completely understood. Acquired
risk factors for thrombosis, often present in IBD patients,
only partially explain the increased thrombotic risk in this
particular population. No relevant association has been
found regarding genetic pro-thrombotic risk factors in
UC and CD patients. Moreover, many quantitative
and qualitative alterations in single components of
cascade factors, fibrinolytic system and natural anticoagu-
lants has been found, but none of them was sufficient per
se to explain the increased thromboembolic risk. What
seems to be the case is that maintaining the pro-thrombotic
tendency in this context is multifactorial, thus coagulation
components and their inhibitors, as well as hemostatic
relevant cells as platelets and endothelial cells, interact in a
context of inflamed mucosa that is chronically activated
and contributes to maintain chronic inflammation as well.
In turn, inflammatory molecules and cytokines have been
demonstrated to imbalance the haemostatic system towards
hyper-coagulability. The two complex mechanisms of
inflammation and coagulation deeply interact in IBD
mucosa amplifying and potentiating each other.
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